Investors & Media
Medical Affairs
Contact

Investors & Media

At Vera Therapeutics, our mission is to pursue truth in science to transform medicine in autoimmune diseases, starting with kidney disease.

Stock Information

Minimum 15 minutes delayed. Source: LSEG

View more

Corporate Presentation

Download

Latest Press Releases

Oct 22, 2026

Vera Therapeutics Announces Positive ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Presented at ASN Kidney Week 2026 and Published in the New England Journal of Medicine

Oct 20, 2026

Vera Therapeutics to Host ASN Kidney Week Investor Webcast and Third Quarter 2026 Financial Results Conference Webcast

Oct 2, 2026

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Events & Presentations

Nov 5, 2026 4:30 PM EST

Third Quarter 2026 Financial Results Investor Webcast

Oct 22, 2026 4:30 PM EDT

Virtual Investor Event: ASN Kidney Week 2026

Sep 15, 2026 5:35 PM EDT

Morgan Stanley 24th Annual Global Healthcare Conference

Contact

INVESTOR INQUIRIES

IR@veratx.com

MEDIA INQUIRIES

corporatecommunications@veratx.com

Leaving this site

The link will take you to a third-party site and is not owned or controlled by Vera. Vera makes no representation as to the accuracy of the information contained on third-party sites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.